Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS)
Fennell, D. Griffiths, D. Eminton, Z. Morgan-Fox, A. Hill, K. Nearchou, T. Johnson, L. Harding, S. Poile, C. Bzura, A.
Fennell, D.
Griffiths, D.
Eminton, Z.
Morgan-Fox, A.
Hill, K.
Nearchou, T.
Johnson, L.
Harding, S.
Poile, C.
Bzura, A.
Citations
Altmetric:
Abstract
Authors
Fennell, D.
Griffiths, D.
Eminton, Z.
Morgan-Fox, A.
Hill, K.
Nearchou, T.
Johnson, L.
Harding, S.
Poile, C.
Bzura, A.
Spicer, J.
Nye, M.
Cave, J.
Danson, S.
Toy, E.
Jain, P.
Steele, N.
Shaw, P.
Taylor, Paul
Szlosarek, P.
Papadatos-Pastos, D.
Lind, M.
Dulloo, S.
Saman, H.
Bajaj, A.
Luo, J. L.
Darlison, L.
Griffiths, G.
Griffiths, D.
Eminton, Z.
Morgan-Fox, A.
Hill, K.
Nearchou, T.
Johnson, L.
Harding, S.
Poile, C.
Bzura, A.
Spicer, J.
Nye, M.
Cave, J.
Danson, S.
Toy, E.
Jain, P.
Steele, N.
Shaw, P.
Taylor, Paul
Szlosarek, P.
Papadatos-Pastos, D.
Lind, M.
Dulloo, S.
Saman, H.
Bajaj, A.
Luo, J. L.
Darlison, L.
Griffiths, G.
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Nearchou T, et al. Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS). Lung cancer (Amsterdam, Netherlands). 2023 Apr;178:S85-S6. PubMed PMID: WOS:000995413600193.